Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide (Control)
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2016-01-20

Last Posted Date: 2025-01-23

Lead Sponsor: University of Chicago

Target Recruit Count: 180

Registration Number: NCT02659293

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Wayne State University - Karmanos Cacner Institute, Detroit, Michigan, United States
🇵🇱
Polish Myeloma Consortium, Poznań, Poland

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: Placebo
Drug: 0.2mg Buprenorphine

First Posted Date: 2016-01-20

Last Posted Date: 2019-05-29

Lead Sponsor: University of Chicago

Target Recruit Count: 38

Registration Number: NCT02659787

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

HealtheRx Survey for Pulmonary Research Registry Recruitment

Not Applicable

Completed

Conditions: COPD
Asthma

Interventions: Other: HealtheRx+
Other: HealtheRx++

First Posted Date: 2016-01-12

Last Posted Date: 2020-04-29

Lead Sponsor: University of Chicago

Target Recruit Count: 41

Registration Number: NCT02653066

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions: Biological: Haplo-Cord Transplant
Procedure: Matched Unrelated Donor Transplant

First Posted Date: 2016-01-07

Last Posted Date: 2021-03-18

Lead Sponsor: University of Chicago

Target Recruit Count: 9

Registration Number: NCT02648932

Locations: 🇺🇸
University of Chicago Cancer Center, Chicago, Illinois, United States

Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation

Not Applicable

Active, not recruiting

Conditions: Pregnancy
Child Development

Interventions: Dietary Supplement: DHA
Dietary Supplement: Sugar pill

First Posted Date: 2016-01-06

Last Posted Date: 2025-04-22

Lead Sponsor: University of Chicago

Target Recruit Count: 168

Registration Number: NCT02647723

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Not Applicable

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Ganetespib
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2015-12-22

Last Posted Date: 2016-05-30

Lead Sponsor: University of Chicago

Registration Number: NCT02637375

Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery

Phase 4

Completed

Conditions: Neuromuscular Blockade
Postoperative Complications

Interventions: Drug: Cisatracurium
Drug: Succinylcholine

First Posted Date: 2015-12-21

Last Posted Date: 2018-07-17

Lead Sponsor: University of Chicago

Target Recruit Count: 100

Registration Number: NCT02635542

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)

Not Applicable

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

Interventions: Behavioral: Video Module Education (VME)
Behavioral: Teach-To-Goal (TTG)

First Posted Date: 2015-11-20

Last Posted Date: 2018-05-24

Lead Sponsor: University of Chicago

Target Recruit Count: 142

Registration Number: NCT02611531

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor

Interventions: Radiation: Stereotactic body radiotherapy (SBRT)
Drug: Pembrolizumab

First Posted Date: 2015-11-18

Last Posted Date: 2024-05-13

Lead Sponsor: University of Chicago

Target Recruit Count: 117

Registration Number: NCT02608385

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

Phase 1

Active, not recruiting

Conditions: Cerebral Cavernous Malformation

Interventions: Other: Placebo
Drug: Atorvastatin

First Posted Date: 2015-11-11

Last Posted Date: 2024-11-07

Lead Sponsor: University of Chicago

Target Recruit Count: 80

Registration Number: NCT02603328

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Home Terms & Conditions Privacy Policy